CytomX Therapeutics (CTMX) Operating Income (2014 - 2026)
CytomX Therapeutics (CTMX) posted Operating Income of -$19.7 million for Q1 2026, up 29.57% on a QoQ basis from -$27.9 million in Q4 2025, and down 186.96% year-over-year from $22.6 million in Q1 2025.
CytomX Therapeutics (CTMX) Operating Income (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Operating Income history runs 13 years deep, the most recent figure standing at -$19.7 million for Q1 2026.
- Quarterly Operating Income fell 186.96% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.7 million (down 279.81% YoY) and the FY2025 annual result came in at -$22.4 million, down 189.47% from the prior year.
- Operating Income was -$19.7 million for Q1 2026 at CytomX Therapeutics, up from -$27.9 million in the prior quarter.
- Across five years, Operating Income topped out at $22.6 million in Q1 2025 and bottomed at -$32.1 million in Q1 2022.
- A 5-year average of -$7.3 million and a median of -$5.7 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income surged 3017.33% — and 2025, when it slumped 483.56%.
- CytomX Therapeutics' Operating Income stood at -$9.5 million in 2022, then soared by 93.63% to -$606000.0 in 2023, then jumped by 3017.33% to $17.7 million in 2024, then plunged by 258.0% to -$27.9 million in 2025, then increased by 29.57% to -$19.7 million in 2026.
- Business Quant data shows CTMX's Operating Income at -$19.7 million in Q1 2026, -$27.9 million in Q4 2025, and -$15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | CytomX Therapeutics | 574.36 Mn | 227.66 Mn | - | -19.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.67 Mn |
| Dec 31, 2025 | -27.93 Mn |
| Sep 30, 2025 | -15.77 Mn |
| Jun 30, 2025 | -1.29 Mn |
| Mar 31, 2025 | 22.62 Mn |
| Dec 31, 2024 | 17.68 Mn |
| Sep 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | -8.45 Mn |
| Mar 31, 2024 | 11.66 Mn |
| Dec 31, 2023 | -606,000.00 |
| Sep 30, 2023 | 3.12 Mn |
| Jun 30, 2023 | -3.35 Mn |
| Mar 31, 2023 | -5.65 Mn |
| Dec 31, 2022 | -9.51 Mn |
| Sep 30, 2022 | -29.71 Mn |
| Jun 30, 2022 | -30.05 Mn |
| Mar 31, 2022 | -32.06 Mn |
| Dec 31, 2021 | -34.90 Mn |
| Sep 30, 2021 | -31.04 Mn |
| Jun 30, 2021 | -26.70 Mn |